Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034131 | 0.90 | ALDH1A1 (0.53) | ALDH1A1CYP3A4USP2HPGDIDO1 | |
| SCHEMBL12160553 | 0.86 | ALDH1A1 (0.57) | ALDH1A1CYP3A4HPGDIDH1HSP90AB1 | |
| SCHEMBL1423103 | 0.84 | TNKS2 (0.42) | ALDH1A1CYP3A4HCAR1USP2HPGD | |
| SCHEMBL12014019 | 0.84 | ALDH1A1 (0.47) | ALDH1A1CYP3A4IDO1IDH1S1PR4 | |
| SCHEMBL11929879 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP3A4USP2HPGDIDO1 | |
| SCHEMBL27777752 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP3A4USP2HPGDIDO1 | |
| SCHEMBL12013414 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP3A4HPGDIDO1IDH1 | |
| SCHEMBL5666942 | 0.80 | ALDH1A1 (0.64) | ALDH1A1CYP3A4IDH1SMN1; SMN2 | |
| SCHEMBL29074791 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP3A4USP2HPGDIDH1 | |
| SCHEMBL8979356 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HPGDS1PR4MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297085-B1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2297085-B1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-8541603-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541603-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2288598-B1 | THIOPHENE DERIVATIVES USEFUL AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2288598-B1 | THIOPHENE DERIVATIVES USEFUL AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2012-03-21 | — | — | EP | disclosed |
| CN-101102989-B | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertension | ALLERGAN INC | 2011-11-16 | — | — | CN | disclosed |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | ALLERGAN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | ALLERGAN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7323591-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323591-B2 | Substituted cyclopentanes or cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101102989-A | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertension | ALLERGAN INC (US) | 2008-01-09 | — | — | CN | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | OLD DAVID W | 2007-11-15 | — | — | US | disclosed |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | OLD DAVID W | 2007-11-15 | — | — | US | disclosed |
| EP-1846354-A2 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES FOR THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | Allergan, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006076370-A2 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES FOR THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | ALDH1A1 883/4885CYP3A4 1182/4885HCAR1 990/4885 |
| US-20080058414-A1 | Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents | CYC1, HSPE1, CYP27A1 | ALDH1A1 1689/4885CYP3A4 2126/4885HCAR1 639/4885 |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | ALDH1A1 1004/4885CYP3A4 2025/4885HCAR1 2891/4885 |
| US-20070265464-A1 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS | HCCS, MCL1, NME4 | ALDH1A1 2087/4885CYP3A4 2876/4885HCAR1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.